Pharma Focus Asia

PCI Pharma to Open New Sterile Fill-Finish Facility in USA

Introduction:

PCI Pharma Services plans to open newest sterile fill-finish facility in USA. 

Features: 

The facility will enhance capacity with Annex 1-compliant technology, featuring an aseptic fill-finish line within a fully isolated containment system, and equipped with twin 430-square-foot lyophilizers with automatic loading and unloading systems. 

The new high-volume lyophilisation and liquid filling facility will add to the ability to provide full product lifecycle management from formulation and lyo cycle development through clinical stages and large commercial-scale sterile manufacturing.

The integrated filler will manufacture batch sizes up to 300,000 vials at a rate of up to 400 vials per minute, providing significant capacity for the filling of late-phase clinical and commercial small molecules and biologics. This includes high-value drug products such as mAbs, oligonucleotides, fusion proteins, and peptides.

The new facility is slated for completion in late fall, with GMP production expected to commence in Q1 2025.

Specifications:

Name    PCI Pharma Services
Type      New Construction
Year      2025


 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference